These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 38057830)

  • 1. Cancer-associated fibroblasts induce sorafenib resistance of hepatocellular carcinoma cells through CXCL12/FOLR1.
    Zhao J; Lin E; Bai Z; Jia Y; Wang B; Dai Y; Zhuo W; Zeng G; Liu X; Cai C; Li P; Zou B; Li J
    BMC Cancer; 2023 Dec; 23(1):1198. PubMed ID: 38057830
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The BAFF/NFκB axis is crucial to interactions between sorafenib-resistant HCC cells and cancer-associated fibroblasts.
    Gao L; Morine Y; Yamada S; Saito Y; Ikemoto T; Tokuda K; Miyazaki K; Okikawa S; Takasu C; Shimada M
    Cancer Sci; 2021 Sep; 112(9):3545-3554. PubMed ID: 34159680
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Extracellular vesicles derived from cancer-associated fibroblasts carry tumor-promotive microRNA-1228-3p to enhance the resistance of hepatocellular carcinoma cells to sorafenib.
    Zhang Y; Pan Q; Shao Z
    Hum Cell; 2023 Jan; 36(1):296-311. PubMed ID: 36424471
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Quantitative proteomics identifies FOLR1 to drive sorafenib resistance via activating autophagy in hepatocellular carcinoma cells.
    Chu H; Wu C; Zhao Q; Sun R; Yang K; Zhao B; Liu Y; Liang Z; Zhong S; Zhang L; Zhang Y
    Carcinogenesis; 2021 May; 42(5):753-761. PubMed ID: 33677528
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nek2 augments sorafenib resistance by regulating the ubiquitination and localization of β-catenin in hepatocellular carcinoma.
    Deng L; Sun J; Chen X; Liu L; Wu D
    J Exp Clin Cancer Res; 2019 Jul; 38(1):316. PubMed ID: 31319849
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Resolvin D1 prevents epithelial-mesenchymal transition and reduces the stemness features of hepatocellular carcinoma by inhibiting paracrine of cancer-associated fibroblast-derived COMP.
    Sun L; Wang Y; Wang L; Yao B; Chen T; Li Q; Liu Z; Liu R; Niu Y; Song T; Liu Q; Tu K
    J Exp Clin Cancer Res; 2019 Apr; 38(1):170. PubMed ID: 30999932
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cancer-associated fibroblast-derived secreted phosphoprotein 1 contributes to resistance of hepatocellular carcinoma to sorafenib and lenvatinib.
    Eun JW; Yoon JH; Ahn HR; Kim S; Kim YB; Lim SB; Park W; Kang TW; Baek GO; Yoon MG; Son JA; Weon JH; Kim SS; Cho HJ; Cheong JY
    Cancer Commun (Lond); 2023 Apr; 43(4):455-479. PubMed ID: 36919193
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cancer‑associated fibroblast‑induced M2‑polarized macrophages promote hepatocellular carcinoma progression via the plasminogen activator inhibitor‑1 pathway.
    Chen S; Morine Y; Tokuda K; Yamada S; Saito Y; Nishi M; Ikemoto T; Shimada M
    Int J Oncol; 2021 Aug; 59(2):. PubMed ID: 34195849
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cancer-associated fibroblasts induce PDL1+ neutrophils through the IL6-STAT3 pathway that foster immune suppression in hepatocellular carcinoma.
    Cheng Y; Li H; Deng Y; Tai Y; Zeng K; Zhang Y; Liu W; Zhang Q; Yang Y
    Cell Death Dis; 2018 Apr; 9(4):422. PubMed ID: 29556041
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Maternal embryonic leucine zipper kinase serves as a potential prognostic marker and leads to sorafenib chemoresistance modified by miR-142-5p in hepatocellular carcinoma.
    Li H; Gai L; Wu Z; Li F
    Mol Biol Rep; 2022 Apr; 49(4):3015-3024. PubMed ID: 35013864
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The LINC00152/miR-205-5p/CXCL11 axis in hepatocellular carcinoma cancer-associated fibroblasts affects cancer cell phenotypes and tumor growth.
    Liu G; Yang ZF; Sun J; Sun BY; Zhou PY; Zhou C; Guan RY; Wang ZT; Yi Y; Qiu SJ
    Cell Oncol (Dordr); 2022 Dec; 45(6):1435-1449. PubMed ID: 36435866
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MiR-375 attenuates sorafenib resistance of hepatocellular carcinoma cells by inhibiting cell autophagy.
    Wang D; Yang J
    Acta Biochim Pol; 2023 Apr; 70(2):239-246. PubMed ID: 37068178
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Loss of exosomal miR-320a from cancer-associated fibroblasts contributes to HCC proliferation and metastasis.
    Zhang Z; Li X; Sun W; Yue S; Yang J; Li J; Ma B; Wang J; Yang X; Pu M; Ruan B; Zhao G; Huang Q; Wang L; Tao K; Dou K
    Cancer Lett; 2017 Jul; 397():33-42. PubMed ID: 28288874
    [TBL] [Abstract][Full Text] [Related]  

  • 14. TARBP2-mediated destabilization of Nanog overcomes sorafenib resistance in hepatocellular carcinoma.
    Lai HH; Li CW; Hong CC; Sun HY; Chiu CF; Ou DL; Chen PS
    Mol Oncol; 2019 Apr; 13(4):928-945. PubMed ID: 30657254
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MiR-25 enhances autophagy and promotes sorafenib resistance of hepatocellular carcinoma via targeting FBXW7.
    Feng X; Zou B; Nan T; Zheng X; Zheng L; Lan J; Chen W; Yu J
    Int J Med Sci; 2022; 19(2):257-266. PubMed ID: 35165511
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cholesterol sensor SCAP contributes to sorafenib resistance by regulating autophagy in hepatocellular carcinoma.
    Li D; Yao Y; Rao Y; Huang X; Wei L; You Z; Zheng G; Hou X; Su Y; Varghese Z; Moorhead JF; Chen Y; Ruan XZ
    J Exp Clin Cancer Res; 2022 Mar; 41(1):116. PubMed ID: 35354475
    [TBL] [Abstract][Full Text] [Related]  

  • 17. LncRNA LIMT (LINC01089) contributes to sorafenib chemoresistance via regulation of miR-665 and epithelial to mesenchymal transition in hepatocellular carcinoma cells.
    Sun J; Zheng X; Wang B; Cai Y; Zheng L; Hu L; Lu X; Xie S; Zhang X; Liu H; Ye L
    Acta Biochim Biophys Sin (Shanghai); 2022 Jan; 54(2):261-270. PubMed ID: 35130616
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Conophylline Inhibits Hepatocellular Carcinoma by Inhibiting Activated Cancer-associated Fibroblasts Through Suppression of G Protein-coupled Receptor 68.
    Yamanaka T; Harimoto N; Yokobori T; Muranushi R; Hoshino K; Hagiwara K; Gantumur D; Handa T; Ishii N; Tsukagoshi M; Igarashi T; Watanabe A; Kubo N; Araki K; Umezawa K; Shirabe K
    Mol Cancer Ther; 2021 Jun; 20(6):1019-1028. PubMed ID: 33722852
    [TBL] [Abstract][Full Text] [Related]  

  • 19. DNMT3b/OCT4 expression confers sorafenib resistance and poor prognosis of hepatocellular carcinoma through IL-6/STAT3 regulation.
    Lai SC; Su YT; Chi CC; Kuo YC; Lee KF; Wu YC; Lan PC; Yang MH; Chang TS; Huang YH
    J Exp Clin Cancer Res; 2019 Nov; 38(1):474. PubMed ID: 31771617
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cancer-associated fibroblast exosomes promote chemoresistance to cisplatin in hepatocellular carcinoma through circZFR targeting signal transducers and activators of transcription (STAT3)/ nuclear factor -kappa B (NF-κB) pathway.
    Zhou Y; Tang W; Zhuo H; Zhu D; Rong D; Sun J; Song J
    Bioengineered; 2022 Mar; 13(3):4786-4797. PubMed ID: 35139763
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.